KRAS Mutation Test in Korean Patients with Colorectal Carcinomas: A Methodological Comparison between Sanger Sequencing and a Real-Time PCR-Based Assay

Lee, Sung Hak; Chung, Arthur Minwoo; Lee, Ahwon; Oh, Woo Jin; Choi, Yeong Jin; Lee, Youn-Soo; Jung, Eun Sun

doi:10.4132/jptm.2016.10.03

Cited by 5 publications

(2 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a study researching KRAS mutation frequencies in Caucasian colorectal cancer patients, KRAS mutations were found in 38.3% [ 65 ]. A study of colorectal cancer patients in South Korea reported that KRAS mutations were found in 45.9% [ 66 ]. Meanwhile, the KRAS mutation rate of primary cancer was higher in this study compared to 30%–40% in previous studies [ 65 , 66 ], which seems to be because the study was conducted on BM patients.…”

Section: Metastatic Colon Cancermentioning

confidence: 99%

“…A study of colorectal cancer patients in South Korea reported that KRAS mutations were found in 45.9% [ 66 ]. Meanwhile, the KRAS mutation rate of primary cancer was higher in this study compared to 30%–40% in previous studies [ 65 , 66 ], which seems to be because the study was conducted on BM patients. RAS mutation analysis in colorectal cancer patients reported that RAS mutations affect the increased incidence of lung, bone and BM [ 67 ].…”

Section: Metastatic Colon Cancermentioning

confidence: 99%

See 1 more Smart Citation

Single-center study on clinicopathological and typical molecular pathologic features of metastatic brain tumor

Kim

Lee

et al. 2023

J Pathol Transl Med

Self Cite

View full text Add to dashboard Cite

Background: The metastatic brain tumor is the most common brain tumor. The aim of this study was to demonstrate the clinicopathological and molecular pathologic features of brain metastases (BM).Methods: A total of 269 patients were diagnosed with BM through surgical resection at Seoul St. Mary’s Hospital from January 2010 to March 2020. We reviewed the clinicopathological features and molecular status of primary and metastatic brain tissues using immunohistochemistry and molecular pathology results.Results: Among 269 patients, 139 males and 130 females were included. The median age of primary tumor was 58 years (range, 13 to 87 years) and 86 patients (32.0%) had BM at initial presentation. Median BM free interval was 28.0 months (range, 1 to 286 months). The most frequent primary site was lung 46.5% (125/269), and followed by breast 15.6% (42/269), colorectum 10.0% (27/269). Epidermal growth factor receptor (<i>EGFR</i>) mutation was found in 50.8% (32/63) and 58.0% (40/69) of lung primary and BM, respectively. In both breast primary and breast cancer with BM, luminal B was the most frequent subtype at 37.9% (11/29) and 42.9% (18/42), respectively, followed by human epidermal growth factor receptor 2 with 31.0% (9/29) and 33.3% (14/42). Triple-negative was 20.7% (6/29) and 16.7% (7/42), and luminal A was 10.3% (3/29) and 7.1% (3/42) of breast primary and BM, respectively. In colorectal primary and colorectal cancer with BM, <i>KRAS</i> mutation was found in 76.9% (10/13) and 66.7% (2/3), respectively.Conclusions: We report the clinicopathological and molecular pathologic features of BM that can provide useful information for understanding the pathogenesis of metastasis and for clinical trials based on the tumor’s molecular pathology.

show abstract

Section: Metastatic Colon Cancermentioning

confidence: 99%

Section: Metastatic Colon Cancermentioning

confidence: 99%

Single-center study on clinicopathological and typical molecular pathologic features of metastatic brain tumor

Kim

Lee

et al. 2023

J Pathol Transl Med

Self Cite

View full text Add to dashboard Cite

show abstract

CRISPR Technology for Breast Cancer: Diagnostics, Modeling, and Therapy

Mintz

Gao

et al. 2018

Adv. Biosys.

View full text Add to dashboard Cite

Molecularly, breast cancer represents a highly heterogenous family of neoplastic disorders, with substantial interpatient variations regarding genetic mutations, cell composition, transcriptional profiles, and treatment response. Consequently, there is an increasing demand for alternative diagnostic approaches aimed at the molecular annotation of the disease on a patient‐by‐patient basis and the design of more personalized treatments. The clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR‐associated (Cas) technology enables the development of such novel approaches. For instance, in diagnostics, the use of the RNA‐specific C2c2 system allows ultrasensitive nucleic acid detection and could be used to characterize the mutational repertoire and transcriptional breast cancer signatures. In disease modeling, CRISPR/Cas9 technology can be applied to selectively engineer oncogenes and tumor‐suppressor genes involved in disease pathogenesis. In treatment, CRISPR/Cas9 can be used to develop gene‐therapy, while its catalytically‐dead variant (dCas9) can be applied to reprogram the epigenetic landscape of malignant cells. As immunotherapy becomes increasingly prominent in cancer treatment, CRISPR/Cas9 can engineer the immune cells to redirect them against cancer cells and potentiate antitumor immune responses. In this review, CRISPR strategies for the advancement of breast cancer diagnostics, modeling, and treatment are highlighted, culminating in a perspective on developing a precision medicine‐based approach against breast cancer.

show abstract

Droplet digital PCR revealed high concordance between primary tumors and lymph node metastases in multiplex screening of KRAS mutations in colorectal cancer

et al. 2019

View full text Add to dashboard Cite

KRAS Mutation Test in Korean Patients with Colorectal Carcinomas: A Methodological Comparison between Sanger Sequencing and a Real-Time PCR-Based Assay

Cited by 5 publications

References 38 publications

Single-center study on clinicopathological and typical molecular pathologic features of metastatic brain tumor

Single-center study on clinicopathological and typical molecular pathologic features of metastatic brain tumor

CRISPR Technology for Breast Cancer: Diagnostics, Modeling, and Therapy

Droplet digital PCR revealed high concordance between primary tumors and lymph node metastases in multiplex screening of KRAS mutations in colorectal cancer

Contact Info

Product

Resources

About